RT Journal Article
SR Electronic
T1 The machine learning algorithm identified COL7A1 as a diagnostic marker for LUSC and HNSC
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.19.23292914
DO 10.1101/2023.07.19.23292914
A1 Wang, Chenyu
A1 Ma, Yongxin
A1 Qi, Jiaojiao
A1 Jiang, Xianglai
YR 2023
UL http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292914.abstract
AB Squamous cell carcinomas (SCCs) comes from different parts, but there may be similar tumorigenic signaling pathways and metabolism, and different squamous cell carcinoma has a similar mutation landscape and squamous differentiation expression. Studying the expression profile of common SCCs is helpful to find biomarkers with diagnostic and prognostic significance for a variety of squamous cell carcinoma. Lung squamous cell carcinoma (LUSC), head and neck squamous cell carcinoma (HNSC), and ‘squamous cell cancer’ in esophageal carcinoma (ESCA) and cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) in The Cancer Genome Atlas (TCGA) database were used as training sets. The relevant data sets in the Gene Expression Omnibus (GEO) database were selected as validation sets. Machine learning algorithms were used to screen out factors with high accuracy in the diagnosis of SCCs as core genes, and explore their effects on patient prognosis and immunotherapy. COL7A1 (Collagen Type VII Alpha 1 Chain) has high accuracy in the diagnosis of LUSC and HCSC, whether in the training set (LUSC _ AUC: 0.987; HNSC _ AUC: 0.933) or validation set (LUSC _ AUC: 1.000; HNSC _ AUC: 0.967). Moreover, the expression of COL7A1 was significantly correlated with shorter OS and DSS in HNSC and LUSC patients, and was also significantly negatively correlated with IPS in LUSC patients treated with CTLA4 (-) PD1 (+), CTLA4 (+) PD1 (-) and CTLA4 (+) PD1 (+). COL7A1 has the potential to be used as a diagnostic and prognostic marker for LUSC and HNSC and to predict the efficacy of LUSC immunotherapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The datasets analyzed during the current study are available in TCGA (https://portal.gdc.cancer.gov/), GEO database (https://www.ncbi.nlm.nih.gov/geo/), TISIDB database (http://cis.hku.hk/TISIDB/) and TCIA database (https://tcia.at/home).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets analyzed during the current study are available in TCGA (https://portal.gdc.cancer.gov/), GEO database (https://www.ncbi.nlm.nih.gov/geo/), TISIDB database (http://cis.hku.hk/TISIDB/) and TCIA database (https://tcia.at/home). https://portal.gdc.cancer.gov/ https://www.ncbi.nlm.nih.gov/geo/ http://cis.hku.hk/TISIDB/ https://tcia.at/home